FDA Approves Regeneron and Ipsen's Breakthrough Treatments for Rare Diseases
The FDA has approved Regeneron's monoclonal antibody, Veopoz (pozelimab), as the first treatment for Chaple disease, a rare hereditary immune disease affecting fewer than 100 people worldwide. The drug is expected to be available to patients this quarter and can be used to treat both adults and children aged one and older, who may experience severe gastrointestinal issues or blood clots due to the condition.